Apalutamide-induced lichenoid reaction in a patient with non-metastatic castrate-resistant prostate cancer.
J Oncol Pharm Pract
; 29(7): 1748-1753, 2023 Oct.
Article
de En
| MEDLINE
| ID: mdl-37282554
ABSTRACT
INTRODUCTION:
Apalutamide is an oral selective androgen receptor inhibitor, approved by the FDA for the treatment of patients with non-metastatic, castration-resistant prostate cancer (M0 CRPC) at high risk of developing metastases and for patients with metastatic castration-sensitive prostate (mHSPC) in association with androgen deprivation therapy (ADT). In the registration studies, skin reactions were reported among the most common side effects and as an adverse event of special interest. CASE REPORT Apalutamide-induced rash includes a wide spectrum of different types of skin reactions, but few cases reports and case series have described this adverse event. Here, we report an M0 CRPC patient who experienced a rare skin adverse event, a lichenoid reaction. MANAGEMENT &OUTCOME:
After 4 months of therapy with apalutamide, the patient reported dorsal pricking and dry skin. Lichenoid reaction was confirmed histologically and its correlation to the drug was demonstrated after pursuing a multidisciplinary approach.DISCUSSION:
To our knowledge, this is one of the first cases of Apalutamide-related lichenoid reaction and this clinical case showed the relevance of a multidisciplinary management when assessing drug-related adverse events. A broader knowledge of the spectrum of drug-related reactions would allow for a better diagnosis and therapy management by both physicians and patients.Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Tumeurs prostatiques résistantes à la castration
Limites:
Humans
/
Male
Langue:
En
Journal:
J Oncol Pharm Pract
Sujet du journal:
FARMACIA
Année:
2023
Type de document:
Article
Pays d'affiliation:
Italie